Autopsy report · NCT04564339
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Cause of deathFunding or business
“Sponsor Decision.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 4 years 7 months before it stopped.
- 123 participants enrolled.
- Results were posted on the registry 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Lupus Nephritis; Immunoglobulin A Nephropathy
- Interventions
- Ravulizumab; Placebo; Background Therapy
- Participants
- 123
- Sites
- 64
- Countries
- Australia, Canada, France, Germany, Italy, Netherlands, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.